The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Royalty Pharma (NASDAQ ...

Eli Lilly and Company stock traded up $6.90 during midday trading on Thursday, hitting $843.91. 1,539,871 shares of the company were exchanged, compared to its average volume of 3,668,910. Eli ...

We recently compiled a list of the 12 Best Low Price Pharma Stocks To Invest In Right Now. In this article, we are going to take a look at where Teva Pharmaceutical Industries Limited (NYSE ...

Shares of LLY stock traded up $11.16 during trading hours on Wednesday, reaching $833.67. The stock had a trading volume of 1,097,779 shares, compared to its average volume of 3,116,302. The stock ...

We recently compiled a list of the 12 Best Small Cap Pharma Stocks to Buy Now. In this article, we are going to take a look at where Collegium Pharmaceutical, Inc. (NASDAQ:COLL) stands against ...

The stock stands eleventh among the best small cap pharma stocks to buy now. Collegium Pharmaceutical, Inc. (NASDAQ:COLL), which focused on pain management historically, has recently expanded into ...

Lexicon Pharmaceuticals LXRX has been analyzed by ... analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference ...

While technology is sometimes a hit-or-miss affair, particularly with the intrusions of innovation occasionally outweighing its conveniences, the best pharmaceutical stocks typically enjoy ...

Companies worth $10 billion or more are generally described as "large-cap stocks," West Pharmaceutical fits right into that category, with its market cap exceeding this threshold, reflecting its ...

Investing.com -- Shares of Lexicon Pharmaceuticals , Inc. (Nasdaq: NASDAQ:LXRX) plummeted 50% following the announcement of topline results from its Phase 2b PROGRESS study, which evaluated the ...

And, although coverage of this company is modest, all eight of the analysts following Catalyst Pharmaceutical rate this stock a buy, with seven of them calling it a strong buy. Generating a ...